DUBLIN, Ireland, Dec. 6, 2010 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals Plc, a publicly listed product development company, today announced the commencement of an oral drug delivery Feasibility and Option agreement with one of the world’s top ten biggest pharmaceutical companies. The agreement will evaluate the ability of Merrion’s patented GIPET® technology to boost the bioavailablity of three of the ‘big pharma’ company’s compounds. The three compounds have a range of molecular weights. Following the feasibility studies, the company will have the option to enter into a licensing agreement for Merrion’s GIPET technology. Merrion’s GIPET technology is a platform technology with broad applicability which covers a wide range of compounds with varying physiochemical properties and molecular weights.
